Capital International Inc. CA Purchases 19,619 Shares of Royalty Pharma PLC $RPRX

Capital International Inc. CA boosted its position in Royalty Pharma PLC (NASDAQ:RPRX) by 3.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 681,155 shares of the biopharmaceutical company’s stock after buying an additional 19,619 shares during the quarter. Capital International Inc. CA’s holdings in Royalty Pharma were worth $24,031,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Capital International Investors grew its stake in Royalty Pharma by 24.4% in the third quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock valued at $960,064,000 after purchasing an additional 5,332,074 shares in the last quarter. Norges Bank bought a new stake in shares of Royalty Pharma during the 2nd quarter worth approximately $181,388,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Royalty Pharma by 118.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,976,480 shares of the biopharmaceutical company’s stock valued at $107,243,000 after buying an additional 1,615,706 shares during the last quarter. Amundi boosted its holdings in shares of Royalty Pharma by 126.1% in the 2nd quarter. Amundi now owns 2,797,471 shares of the biopharmaceutical company’s stock valued at $101,240,000 after buying an additional 1,560,093 shares during the last quarter. Finally, Jupiter Asset Management Ltd. grew its stake in shares of Royalty Pharma by 126.5% in the second quarter. Jupiter Asset Management Ltd. now owns 2,470,706 shares of the biopharmaceutical company’s stock valued at $89,020,000 after buying an additional 1,380,115 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on RPRX shares. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Weiss Ratings raised shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, February 12th. Morgan Stanley reaffirmed an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a report on Thursday, February 12th. Finally, Citigroup raised their target price on shares of Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $48.67.

Royalty Pharma Stock Up 0.3%

RPRX opened at $45.97 on Wednesday. The stock’s fifty day simple moving average is $42.81 and its 200 day simple moving average is $39.37. Royalty Pharma PLC has a 1-year low of $29.66 and a 1-year high of $47.86. The stock has a market cap of $26.52 billion, a PE ratio of 34.05 and a beta of 0.40. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The firm had revenue of $621.99 million during the quarter, compared to analysts’ expectations of $839.97 million. As a group, research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Friday, February 20th were issued a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s payout ratio is presently 69.63%.

Insider Activity

In related news, EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Terrance P. Coyne sold 34,791 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $46.78, for a total transaction of $1,627,522.98. Following the completion of the transaction, the chief financial officer directly owned 45,761 shares in the company, valued at approximately $2,140,699.58. This represents a 43.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 737,078 shares of company stock valued at $29,862,002 in the last ninety days. 18.90% of the stock is currently owned by insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.